8-K: Quanterix Q2 Revenue Drops 29%; Shifts to Majority Director Vote

Quanterix Corporation reported a 29% revenue decrease in Q2 2025, alongside a significant net loss, while also adopting a majority voting standard for uncontested director elections.

Summary

• Q2 2025 revenue was $24.5 million, a 29% decrease from $34.4 million in Q2 2024.
• Net loss for Q2 2025 was $30.0 million, significantly higher than the $7.4 million net loss in Q2 2024.
• GAAP gross margin declined to 46.2% from 64.7% year-over-year.
• The company completed the acquisition of Akoya Biosciences in early July 2025, creating an integrated platform for biomarker detection.
• Alzheimer's Diagnostics revenues more than tripled year-over-year.
• Quanterix has captured 75% of its $85 million synergy and cost reduction target, with $64 million already implemented.
• The Board of Directors approved amended bylaws to implement a majority voting standard for uncontested director elections, effective August 5, 2025.

Sentiment

Score: 4

Explanation: While the company highlights strategic acquisitions and cost synergies, the significant year-over-year decline in revenue, widening net loss, and reduced gross margins indicate substantial operational challenges. The positive outlook for cost reductions and future cash flow breakeven is forward-looking and contingent on successful execution in a difficult market.

Positives

• Successful acquisition of Akoya Biosciences, creating an integrated platform for biomarker detection across blood and tissue.
• Achieved 75% ($64 million) of the $85 million synergy and cost reduction target.
• Alzheimer's Diagnostics revenues more than tripled year-over-year.
• Accelerator business reported a net increase in new customers.
• UltraDx Plasma pTau-217 Assay Kit received medical device registration approval from China's FDA.
• Targeting cash flow breakeven in 2026.

Negatives

• Revenue decreased by 29% to $24.5 million in Q2 2025 compared to the prior year.
• Net loss significantly widened to $30.0 million in Q2 2025 from $7.4 million in Q2 2024.
• GAAP gross margin decreased to 46.2% from 64.7% in the prior year.
• Adjusted gross margin (non-GAAP) also declined to 41.8% from 58.6%.
• The Accelerator business experienced smaller project sizes due to constrained biopharma budgets.
• Recent weakness observed in the U.S. academic and pharmaceutical end markets.

Risks

• Impact of recent U.S. government policies, including reductions in federal research funding and increased tariffs.
• Failure to realize the expected benefits of cost reduction actions.
• Risks associated with the anticipated timing for launch of, and features of, Quanterix's next-generation instrument, Simoa One.
• Risks that Quanterix may fail to realize the anticipated benefits and synergies of its recent acquisition of Emission, Inc.
• Risks that Quanterix's estimates regarding expenses, future revenues, capital requirements, and needs for additional financing could be incorrect.
• Risks related to the restatement of Quanterix's consolidated financial statements, including increased costs and the increased possibility of legal proceedings and regulatory inquiries, sanctions, or investigation.
• Risks related to Quanterix's ability to maintain effective internal control over financial reporting and disclosure controls and procedures, including its ability to remediate existing material weaknesses.
• Risks related to Quanterix's ability to realize the intended benefits of its assay redevelopment program.
• Risks related to Quanterix's ability to retain and expand its customer base and achieve sufficient market acceptance of its products.
• Risks that the anticipated benefits and synergies of the acquisition of Akoya Biosciences are not realized when expected or at all, including as a result of the impact of, or problems arising from, the integration of the two companies or as a result of the strength of the economy and competitive factors.

Future Outlook

Quanterix expects full-year 2025 revenues between $130 million and $135 million, or $165 million to $170 million on a pro forma combined basis with Akoya. The company anticipates GAAP gross margin of 49% to 53% and adjusted cash usage of $34 million to $38 million for 2025. Management aims to exit 2025 with approximately $120 million in cash and achieve cash flow breakeven in 2026.

Management Comments

• "Through our combination with Akoya Biosciences, we have created a high-margin, high-throughput business with a compelling opportunity to deliver profitable growth in an expanded market." Masoud Toloue, CEO
• "We have built a franchise that is generating approximately $100 million of consumables revenue, on a pro forma basis, and demonstrating resiliency in the face of near-term challenges in the US academic market." Masoud Toloue, CEO
• "Within the quarter, our Accelerator business reported a net increase in new customers, despite smaller project sizes due to constrained biopharma budgets." Masoud Toloue, CEO
• "Additionally, our Alzheimer's Diagnostics revenues more than tripled year-over-year." Masoud Toloue, CEO
• "We took decisive actions to position the business for long-term growth while driving cost reductions, capturing efficiencies and advancing key strategic initiatives." Masoud Toloue, CEO
• "As of today, we have already captured 75% of our $85 million synergy and cost reduction target." Masoud Toloue, CEO
• "We remain focused on maximizing the significant potential of the Akoya combination and achieving cash flow breakeven in 2026, even if end market conditions remain difficult." Masoud Toloue, CEO

Industry Context

The company operates in the ultra-sensitive biomarker detection and spatial biology markets, which are critical for disease research, diagnostics, and drug development. The reported weakness in the U.S. academic and pharmaceutical end markets indicates broader industry challenges, potentially impacting research budgets and project sizes. The acquisition of Akoya Biosciences positions Quanterix to offer an integrated platform across blood and tissue analysis, a strategic move to expand market reach and address comprehensive biomarker profiling needs in precision medicine.

Corporate Governance

Stakeholder Impact

• Shareholders: The significant decline in revenue and increased net loss could negatively impact shareholder value in the short term. However, the strategic acquisition of Akoya, aggressive cost reduction targets, and a clear path to cash flow breakeven in 2026 aim to create long-term value. The change to majority voting for directors enhances shareholder influence in uncontested elections.
• Employees: The ongoing cost reduction and synergy capture initiatives, including combining commercial, operations, and lab services teams, may lead to workforce adjustments or integration challenges.
• Customers: The launch of new p-Tau assays and China FDA approval for the pTau-217 Assay Kit expands product offerings and market access, potentially benefiting customers in Alzheimer's research and diagnostics. However, constrained biopharma budgets could impact project sizes.
• Suppliers: No direct impact mentioned, but cost reduction efforts could lead to renegotiations or changes in supplier relationships.
• Creditors: The company's cash position of $263.8 million at quarter-end, despite cash usage, and the target of $120 million by year-end, along with the goal of cash flow breakeven in 2026, suggest a focus on financial stability, which is positive for creditors.

Next Steps

• Continue integrating Akoya Biosciences.
• Further implement cost reduction actions to achieve the full $85 million synergy target.
• Work towards achieving cash flow breakeven in 2026.
• Continue building the foundation for Alzheimer's diagnostics, including forming new partnerships and expanding international regulatory footprint.

Key Dates

Recommendation

While Quanterix reported a substantial decline in Q2 revenue and a widened net loss, indicating near-term operational challenges and market headwinds, the strategic acquisition of Akoya Biosciences and aggressive cost reduction initiatives are positive long-term catalysts. The company's clear path to cash flow breakeven in 2026 and strong cash position provide some stability. However, the current financial performance and market uncertainties warrant a 'hold' recommendation, as investors should monitor the successful integration of Akoya, the realization of cost synergies, and improvement in end-market conditions before considering further investment.

Keywords

Biomarker Detection, Spatial Biology, Diagnostics, Alzheimer's Research, Life Sciences, Medical Devices, Biopharma, SEC Filing, Financial Results, Corporate Governance, Acquisition, QTRX